| Literature DB >> 23595524 |
W J Pasman1, M J van Erk, W A A Klöpping, L Pellis, S Wopereis, S Bijlsma, H F J Hendriks, A F M Kardinaal.
Abstract
We aimed to explore whether vegetable consumption according to guidelines has beneficial health effects determined with classical biomarkers and nutrigenomics technologies. Fifteen lean (age 36 ± 7 years; BMI 23.4 ± 1.7 kg m(-2)) and 17 obese (age 40 ± 6 years; BMI 30.3 ± 2.4 kg m(-2)) men consumed 50- or 200-g vegetables for 4 weeks in a randomized, crossover trial. Afterward, all subjects underwent 4 weeks of energy restriction (60 % of normal energy intake). Despite the limited weight loss of 1.7 ± 2.4 kg for the lean and 2.1 ± 1.9 kg for the obese due to energy restriction, beneficial health effects were found, including lower total cholesterol, LDL cholesterol and HbA1c concentrations. The high vegetable intake resulted in increased levels of plasma amino acid metabolites, decreased levels of 9-HODE and prostaglandin D3 and decreased levels of ASAT and ALP compared to low vegetable intake. Adipose tissue gene expression changes in response to vegetable intake were identified, and sets of selected genes were submitted to network analysis. The network of inflammation genes illustrated a central role for NFkB in (adipose tissue) modulation of inflammation by increased vegetable intake, in lean as well as obese subjects. In obese subjects, high vegetable intake also resulted in changes related to energy metabolism, adhesion and inflammation. By inclusion of sensitive omics technologies and comparing the changes induced by high vegetable intake with changes induced by energy restriction, it has been shown that part of vegetables' health benefits are mediated by changes in energy metabolism, inflammatory processes and oxidative stress.Entities:
Year: 2013 PMID: 23595524 PMCID: PMC3755133 DOI: 10.1007/s12263-013-0343-9
Source DB: PubMed Journal: Genes Nutr ISSN: 1555-8932 Impact factor: 5.523
Baseline characteristics and fasting blood data of the lean (n = 15) and obese (n = 17) men who completed the study (mean ± SD is presented)
| Parameter | Lean ( | Obese ( |
|
|---|---|---|---|
| Age (years) | 36 ± 7 | 40 ± 6 | N.S. |
| Body weight (kg) | 82.9 ± 9.2 | 101.4 ± 11.4 | <0.001 |
| BMI (kg m−2) | 23.4 ± 1.7 | 30.3 ± 2.4 | <0.001 |
| Waist circumference (cm) | 88.9 ± 4.8 | 105.6 ± 6.6 | <0.001 |
| Waist–hip ratio | 0.89 ± 0.04 | 0.97 ± 0.04 | <0.001 |
| Systolic blood pressure (mm Hg) | 120 ± 13 | 127 ± 12 | N.S. |
| Diastolic blood pressure (mm Hg) | 79 ± 9 | 83 ± 11 | N.S. |
| Glucose (mmol/L) | 5.5 ± 0.4 | 5.6 ± 0.4 | N.S. |
| Insulin (mmol/L) | 6.2 ± 2.4 | 12.9 ± 6.5 | <0.05 |
| HbA1c (%) | 5.1 ± 0.2 | 5.0 ± 0.2 | N.S. |
| Total cholesterol (mmol/L) | 4.9 ± 0.6 | 5.7 ± 0.7 | <0.05 |
| HDL-cholesterol (mmol/L) | 1.3 ± 0.3 | 1.2 ± 0.2 | + |
| LDL-cholesterol (mmol/L) | 3.0 ± 0.4 | 3.6 ± 0.5 | <0.05 |
+ Represents a tendency (p < 0.1); N.S. means not significant
Changes in blood parameters after the energy-restricted (ER) intervention (mean ± SD is presented)
| Treatment | Lean ( | Obese ( |
| ||
|---|---|---|---|---|---|
| Before ER | After ER | Before ER | After ER | ||
| Glucose (mmol/L) | 5.4 ± 0.3 | 5.5 ± 0.3 | 5.7 ± 0.3 | 5.7 ± 0.4 | N.S. |
| Insulin (mU/L) | 5.9 ± 3.3 | 5.0 ± 2.7 | 12.7 ± 6.1 | 11.0 ± 6.8 | N.S. |
| HbA1c (%) | 5.1 ± 0.2 | 5.0 ± 0.2 | 5.1 ± 0.2 | 5.0 ± 0.1 | <0.05 |
| Total cholesterol (mmol/L) | 5.2 ± 0.7 | 4.7 ± 0.7 | 6.0 ± 0.7 | 5.4 ± 0.5 | <0.05 |
| HDL-cholesterol (mmol/L) | 1.3 ± 0.4 | 1.3 ± 0.3 | 1.2 ± 0.2 | 1.1 ± 0.2 | N.S. |
| LDL-cholesterol (mmol/L) | 3.3 ± 0.6 | 2.9 ± 0.6 | 3.9 ± 0.6 | 3.5 ± 0.4 | <0.05 |
| Ratio cholesterol/HDL | 4.3 ± 1.2 | 3.8 ± 0.9 | 5.3 ± 0.9 | 4.9 ± 0.9 | <0.05 |
| Triacylglycerol (mmol/L) | 1.4 ± 0.7 | 1.1 ± 0.5 | 2.2 ± 1.2 | 2.1 ± 1.4 | N.S. |
| γ-GT (U/L) | 23.4 ± 11.2 | 18.2 ± 8.0 | 33.9 ± 12.8 | 27.5 ± 12.5 | <0.05 |
| ALAT (U/L) | 12 ± 4 | 12 ± 4 | 19 ± 11 | 19 ± 11 | N.S. |
| ASAT (U/L) | 21 ± 4 | 20 ± 4 | 26 ± 8 | 24 ± 6 | + |
| ALP (U/L) | 64 ± 12 | 60 ± 10 | 67 ± 18 | 65 ± 14 | N.S. |
| TNF-α (pg/mL)a | 0.97 ± 0.29 | 0.88 ± 0.18 | 1.08 ± 0.34 | 1.11 ± 0.39 | N.S. |
# p values for treatment effect in 2-way ANOVA, interaction effects (BMI-category × treatment) were not significant
+ p < 0.1 (tendency)
aTwo lean subjects were excluded from the TNF-α dataset because they were outliers, ER energy restriction
Changes in blood clinical chemistry parameters after the vegetable intervention (mean ± SD is presented)
| Treatment | Lean ( | Obese ( |
| ||
|---|---|---|---|---|---|
| 50-g Veg | 200-g Veg | 50-g Veg | 200-g Veg | ||
| Glucose (mmol/L) | 5.4 ± 0.3 | 5.4 ± 0.3 | 5.7 ± 0.4 | 5.9 ± 0.1 | N.S. |
| Insulin (mU/L) | 5.5 ± 2.6 | 5.9 ± 3.2 | 11.0 ± 5.2 | 13.4 ± 6.7 | N.S. |
| HbA1c (%) | 5.1 ± 0.2 | 5.1 ± 0.2 | 5.1 ± 0.1 | 5.1 ± 0.2 | N.S. |
| Total cholesterol (mmol/L) | 5.1 ± 0.7 | 5.2 ± 0.6 | 6.0 ± 0.8 | 5.8 ± 0.7 | N.S. |
| HDL-cholesterol (mmol/L) | 1.3 ± 0.3 | 1.3 ± 0.3 | 1.2 ± 0.2 | 1.1 ± 0.2 | N.S. |
| LDL-cholesterol (mmol/L) | 3.2 ± 0.6 | 3.4 ± 0.4 | 3.9 ± 0.6 | 3.8 ± 0.6 | N.S. |
| Ratio cholesterol/HDL | 4.2 ± 1.2 | 4.2 ± 0.9 | 5.3 ± 0.9 | 5.3 ± 0.9 | N.S. |
| Triacylglycerol (mmol/L) | 1.3 ± 0.7 | 1.2 ± 0.5 | 2.2 ± 1.2 | 2.2 ± 1.7 | N.S. |
| γ-GT (U/L) | 23.3 ± 10.9 | 22.4 ± 10.8 | 34.3 ± 13.1 | 32.9 ± 11.6 | N.S. |
| ALAT (U/L) | 13 ± 4 | 11 ± 4 | 21 ± 15 | 21 ± 10 | N.S. |
| ASAT (U/L) | 21 ± 4 | 20 ± 4 | 26 ± 8 | 25 ± 8 | <0.05 |
| ALP (U/L) | 63 ± 11 | 61 ± 11 | 67 ± 18 | 64 ± 15 | <0.05 |
| TNF-α (pg/mL)a | 1.03 ± 0.28 | 0.84 ± 0.17 | 1.11 ± 0.41 | 1.09 ± 0.36 | 0.0067* |
# p values for treatment effect in 2-way ANOVA, interaction effects (BMI-category × treatment) were not significant
* p value for vegetable effect in lean subjects (post hoc test); p value for interaction (BMI-category × treatment) was 0.0491
aTwo lean subjects were excluded from the TNF-α dataset because they were outliers; g, gram and Veg, vegetable
Significant changes in blood metabolites after the vegetables intervention (mean ± SD is presented)
| Treatment | Lean ( | Obese ( |
| ||
|---|---|---|---|---|---|
| 50-g Veg | 200-g Veg | 50-g Veg | 200-g Veg | ||
| Asparagine (Asn) | 0.30 ± 0.06 | 0.32 ± 0.06 | 0.28 ± 0.05 | 0.30 ± 0.07 | 0.0418 |
| Leucine (Leu) | 1.61 ± 0.13 | 1.65 ± 0.15 | 1.83 ± 0.33 | 1.96 ± 0.36 | 0.0224 |
| Methionine sulfoxide 1 | 1.9 × 10−3 ± 8.8 × 10−4 | 2.2 × 10−3 ± 2.9 × 10−4 | 1.9 × 10−3 ± 3.7 × 10−4 | 2.2 × 10−3 ± 5.7 × 10−4 | 0.0308 |
| Methionine sulfoxide 2 | 2.7 × 10−3 ± 1.2 × 10−3 | 2.9 × 10−3 ± 4.2 × 10−4 | 2.6 × 10−3 ± 6.7 × 10−4 | 3.1 × 10−3 ± 7.2 × 10−4 | 0.0455 |
| Threonine (Thr) | 2.32 ± 0.25 | 2.37 ± 0.28 | 2.26 ± 0.39 | 2.49 ± 0.53 | 0.0205 |
| 9-HODE | 2.62 ± 0.83 | 2.20 ± 1.30 | 3.00 ± 1.31 | 2.21 ± 0.46 | 0.0187 |
| PGD-3 | 0.024 ± 0.024 | 0.020 ± 0.021 | 0.017 ± 0.016 | 0.013 ± 0.016 | 0.0408 |
| 15-HETE | 0.08 ± 0.03 | 0.10 ± 0.05 | 0.12 ± 0.06 | 0.08 ± 0.04 | 0.0263* |
G gram; Veg vegetable
p values for treatment effect in 2-way ANOVA, interaction effects (BMI-category × treatment) were not significant
* p value for vegetable effect in obese subjects (post hoc test); p value for interaction (BMI-category × treatment) was 0.006
Fig. 1Enrichment analysis of 641 genes with high correlation to body weight change in 10 obese subjects
Expression changes in obese subjects in response to high vegetable intake compared to low vegetable intake related to inflammation, energy metabolism and adhesion
| Definition | Symbol | Probe_Id | Entrez Gene ID | Mean 2log ratio | |
|---|---|---|---|---|---|
| Energy metabolism | |||||
| Glutamate-ammonia ligase (glutamine synthetase) (GLUL), transcript variant 3, mRNA | GLUL | ILMN_1765208 | 2752 | 0.67 | a |
| Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (RUNX1T1), transcript variant 3, mRNA | RUNX1T1 | ILMN_1710522 | 862 | 0.65 | a |
| Peroxisome proliferator-activated receptor gamma, coactivator-related 1 (PPRC1), mRNA | PPRC1 | ILMN_1796210 | 23082 | 0.65 | b |
| SLIT-ROBO Rho GTPase activating protein 2 (SRGAP2), transcript variant 1, mRNA | SRGAP2 | ILMN_1759549 | 23380 | 0.57 | b |
| Pyruvate carboxylase (PC), nuclear gene encoding mitochondrial protein, transcript variant 3, mRNA | PC | ILMN_1736689 | 5091 | 0.44 | a |
| FERM domain containing 6 (FRMD6), transcript variant 2, mRNA | FRMD6 | ILMN_2330787 | 122786 | 0.42 | b |
| Solute carrier family 25, member 29 (SLC25A29), nuclear gene encoding mitochondrial protein, mRNA | SLC25A29 | ILMN_2350801 | 123096 | 0.40 | b |
| Solute carrier family 25 (mitochondrial carrier, brain), member 14 (SLC25A14), nuclear gene encoding mitochondrial protein, transcript variant long, mRNA | SLC25A14 | ILMN_1743770 | 9016 | 0.39 | a |
| Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain (ACADS), nuclear gene encoding mitochondrial protein, mRNA | ACADS | ILMN_1795104 | 35 | −0.27 | b |
| DNA replication helicase 2 homolog (yeast) (DNA2), mRNA | DNA2 | ILMN_2282959 | 1763 | −0.57 | b |
| Protein kinase C, alpha binding protein (PRKCABP), mRNA | PRKCABP | ILMN_1708159 | 9463 | −0.67 | a |
| Apolipoprotein O-like (APOOL), mRNA | APOOL | ILMN_1777483 | 139322 | −0.68 | a |
| Acyl-CoA synthetase medium-chain family member 5 (ACSM5), mRNA | ACSM5 | ILMN_1801698 | 54988 | −0.71 | a |
| Estrogen receptor 2 (ER beta) (ESR2), transcript variant b, mRNA | ESR2 | ILMN_2390457 | 2100 | −0.74 | a |
| PREDICTED: coiled-coil domain containing 56 (CCDC56), misc RNA | CCDC56 | ILMN_1789786 | 28958 | −0.86 | a |
| Component of oligomeric golgi complex 8 (COG8), mRNA | COG8 | ILMN_1725246 | 84342 | −1.09 | b |
| Adhesion | |||||
| Presenilin 1 (Alzheimer disease 3) (PSEN1), mRNA | PSEN1 | ILMN_1796669 | 5663 | 1.13 | a |
| PREDICTED: p21 (CDKN1A)-activated kinase 2 (PAK2), mRNA | PAK2 | ILMN_1659878 | 5062 | 0.96 | a |
| Reelin (RELN), transcript variant 1, mRNA | RELN | ILMN_1753005 | 5649 | 0.89 | b |
| LIM and senescent cell antigen-like domains 1 (LIMS1), mRNA | LIMS1 | ILMN_2381037 | 3987 | 0.71 | b |
| Dystonin (DST), transcript variant 1e, mRNA | DST | ILMN_1675992 | 667 | 0.70 | a |
| Rap guanine nucleotide exchange factor (GEF) 1 (RAPGEF1), transcript variant 2, mRNA | RAPGEF1 | ILMN_1678799 | 2889 | 0.50 | a |
| Protocadherin 9 (PCDH9), transcript variant 2, mRNA | PCDH9 | ILMN_2379626 | 5101 | 0.46 | b |
| Phosphoglucomutase 5 (PGM5), mRNA | PGM5 | ILMN_2271149 | 5239 | 0.45 | b |
| Periostin, osteoblast specific factor (POSTN), mRNA | POSTN | ILMN_1790761 | 10631 | 0.44 | b |
| Claudin 15 (CLDN15), transcript variant 2, mRNA | CLDN15 | ILMN_1708267 | 24146 | 0.38 | a |
| PREDICTED: p21 (CDKN1A)-activated kinase 2 (PAK2), mRNA | PAK2 | ILMN_1676385 | 5062 | 0.38 | a |
| Polycystic kidney and hepatic disease 1 (autosomal recessive) (PKHD1), transcript variant 1, mRNA | PKHD1 | ILMN_1720034 | 5314 | −0.30 | b |
| Cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila) (CELSR1), mRNA | CELSR1 | ILMN_1694482 | 9620 | −0.50 | b |
| v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) (AKT3), transcript variant 2, mRNA | AKT3 | ILMN_1733598 | 10000 | −0.59 | b |
| Junction plakoglobin (JUP), transcript variant 2, mRNA | JUP | ILMN_2366864 | 3728 | −0.67 | a |
| Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 4 (MLLT4), transcript variant 3, mRNA | MLLT4 | ILMN_1746277 | 4301 | −0.77 | b |
| Cadherin-like 24 (CDH24), transcript variant 1, mRNA | CDH24 | ILMN_1693928 | 64403 | −0.83 | a |
| Rap guanine nucleotide exchange factor (GEF) 1 (RAPGEF1), transcript variant 1, mRNA | RAPGEF1 | ILMN_1695282 | 2889 | −0.93 | b |
| Inflammation | |||||
| Presenilin 1 (Alzheimer disease 3) (PSEN1), mRNA | PSEN1 | ILMN_1796669 | 5663 | 1.13 | a |
| Cathepsin C (CTSC), transcript variant 2, mRNA | CTSC | ILMN_1689086 | 1075 | 0.78 | b |
| Membrane-associated ring finger (C3HC4) 8 (MARCH8), transcript variant 6, mRNA | MARCH8 | ILMN_2341626 | 220972 | 0.78 | a |
| Interleukin 7 receptor (IL7R), mRNA | IL7R | ILMN_2342579 | 3575 | 0.73 | a |
| Interleukin 8 (IL8), mRNA | IL8 | ILMN_2184373 | 3576 | 0.66 | a |
| Tumor necrosis factor receptor superfamily, member 13C (TNFRSF13C), mRNA | TNFRSF13C | ILMN_1731742 | 115650 | 0.63 | a |
| Colony stimulating factor 1 (macrophage) (CSF1), transcript variant 4, mRNA | CSF1 | ILMN_1805930 | 1435 | 0.52 | b |
| Epstein-Barr virus-induced 3 (EBI3), mRNA | EBI3 | ILMN_1802653 | 10148 | 0.51 | a |
| Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F (APOBEC3F), transcript variant 1, mRNA | APOBEC3F | ILMN_1710726 | 200316 | 0.49 | b |
| Neutrophil cytosolic factor 1 (NCF1), mRNA | NCF1 | ILMN_1697309 | 653361 | 0.38 | a |
| Cathepsin C (CTSC), transcript variant 1, mRNA | CTSC | ILMN_2242463 | 1075 | 0.34 | b |
| B and T lymphocyte associated (BTLA), transcript variant 1, mRNA | BTLA | ILMN_1778536 | 151888 | −0.19 | a |
| Chemokine (C-X-C motif) receptor 5 (CXCR5), transcript variant 2, mRNA | CXCR5 | ILMN_2337931 | 643 | −0.42 | a |
| Interleukin 1 receptor, type II (IL1R2), transcript variant 2, mRNA | IL1R2 | ILMN_1772131 | 7850 | −0.60 | b |
| Lymphocyte transmembrane adaptor 1 (LAX1), mRNA | LAX1 | ILMN_1769782 | 54900 | −0.61 | a |
| Serum amyloid A1 (SAA1), transcript variant 1, mRNA | SAA1 | ILMN_1701017 | 6288 | −0.68 | b |
| Virus-induced signaling adapter (VISA), mRNA | VISA | ILMN_2131493 | 57506 | −0.69 | a |
| Tumor necrosis factor (ligand) superfamily, member 12 (TNFSF12), transcript variant 2, mRNA | TNFSF12 | ILMN_1680003 | 8742 | −0.75 | a |
| Serum amyloid A1 (SAA1), transcript variant 1, mRNA | SAA1 | ILMN_1808732 | 6288 | −1.29 | a |
a: p for interaction between intervention and group <0.05; b: p for intervention <0.05. Genes showed consistent expression change in obese subjects (>25 % up or >25 % down in at least 6 subjects)
Fig. 2Network showing biological links between genes involved in inflammation and plasma markers that respond to high vegetable intake in lean subjects. Red circle indicates up-regulation in response to high vegetable intake, blue circle indicates down-regulation in response to high vegetable intake. BAFF-R tumor necrosis factor receptor superfamily, member 13C; Bcl-3 B cell CLL/lymphoma 3; C3 complement component 3; CCL28 chemokine (C–C motif) ligand 28; CCR10 chemokine (C–C motif) receptor 10; CSF1 colony stimulating factor 1 (macrophage); Factor H complement factor H; IL-8: interleukin 8; MASP1: mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor); NF-kB: nuclear factor-kappa-B; NFKBIB I-kappa-B-beta; PPAR-γ peroxisome proliferator-activated receptor gamma; TNF-α tumor necrosis factor alpha; VISA mitochondrial antiviral signaling protein
Fig. 3Network showing biological links between genes involved in inflammation and plasma markers that respond to high vegetable intake in obese subjects. Red circle indicates up-regulation in response to high vegetable intake, blue circle indicates down-regulation in response to high vegetable intake. APOBEC3F: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F; BAFF-R tumor necrosis factor receptor superfamily, member 13C; CSF1 colony stimulating factor 1 (macrophage); EBIB Epstein–Barr virus-induced 3, IL-27 subunit beta; CXCR5 chemokine (C-X-C motif) receptor 5; 15(S)-HETE 15-HETE; IL1R2: interleukin-1 receptor type 2; IL-8 interleukin-8; IL-27 interleukin-27; IL-35 interleukin-35; LAX1 lymphocyte transmembrane adaptor 1; Lck tyrosine-protein kinase Lck; MARCH8 (c-MIR) membrane-associated ring finger (C3HC4) 8; NF-kB nuclear factor-kappa-B; p47-phox neutrophil cytosolic factor 1; PPAR-γ peroxisome proliferator-activated receptor gamma; RXR-α retinoid X receptor, alpha; SAA1 serum amyloid A1; STAT1 signal transducer and activator of transcription 1; STAT5 signal transducer and activator of transcription 5; TRAF3 TNF receptor-associated factor 3; VISA mitochondrial antiviral signaling protein
Fig. 4Network showing biological links between genes involved in energy metabolism and plasma markers that respond to high vegetable intake in obese subjects. Red circle indicates up-regulation in response to high vegetable intake, blue circle indicates down-regulation in response to high vegetable intake. AATC glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1); ALPL alkaline phosphatase, liver/bone/kidney; C/EBP CCAAT/enhancer binding protein (C/EBP); COG complex component of oligomeric golgi complex; COG5 component of oligomeric golgi complex 5; COG8 component of oligomeric golgi complex 8; CREB1 cAMP responsive element binding protein 1; c-Myc v-myc myelocytomatosis viral oncogene homolog (avian); ESR1 (nuclear) estrogen receptor 1; ESR2 estrogen receptor 2 (ER beta); ETO runt-related transcription factor 1; translocated to, 1 (cyclin D-related); FKHR forkhead box O1; GATA-1 GATA binding protein 1 (globin transcription factor 1); GLNA glutamate-ammonia ligase; 15(S)-HETE 15S-hydroxyeicosatetraenoic acid; 15-HETE 15-hydroxyeicosatetraenoic acid; HOXA10 homeobox A10; PPAR-γ peroxisome proliferator-activated receptor gamma; RXR-α retinoid X receptor, alpha; PRC (PGC-1 related) peroxisome proliferator-activated receptor gamma, coactivator-related 1; PYC pyruvate carboxylase; SP1 Sp1 transcription factor; SRGAP2 SLIT-ROBO Rho GTPase activating protein 2; STAT5A signal transducer and activator of transcription 5A; Willin FERM domain containing 6